AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Alliance to develop, commercialize influenza vaccines.
2004 FEB 4 - (NewsRx.com & NewsRx.net) -- Aventis (AVE) and Crucell N.V. (CRXL) announced that they have entered into a strategic agreement to further develop and commercialize novel influenza vaccine products based on Crucell's proprietary PER.C6 cell line technology.
The agreement covers both pandemic and epidemic influenza vaccines, which up to now have been part of Crucell's in-house product development program.
Under the terms of the agreement, Aventis Pasteur, the vaccines business of Aventis, receives an exclusive license to research, develop, manufacture, and market cell-based influenza vaccines using Crucell's unique PER.C6 cell line technology. Crucell will receive milestone payments, annual payments, and research and development funding totaling EUR 30 million, and high single- up to double-digit royalties on future PER.C6-based influenza vaccine sales.
Crucell retains the commercialization rights for Japan, which accounts for 15% of the global influenza vaccine market that, in 2002 totaled EUR 1.2 billion. For Japan, Aventis Pasteur will supply finished vaccine products to Crucell, and Crucell will pay a royalty on sales to Aventis Pasteur.
In 2002, Aventis Pasteur's consolidated influenza vaccine product sales totaled EUR 460 million; representing a 38% global market share.
"PER.C6 ...
- Aventis Pasteur licenses Crucell technology. (Biotechnology).(Brief Article)
- Magazine article from: Chemical Week Sissell, Kara February 12, 2003 700+ words
Aventis Pasteur (Lyon, France) says it has...antibody and vaccine company Crucell (Leiden, the Netherlands), under which Crucell will license its mammalian...Aventis says it will pay Crucell an undisclosed amount in up...
- Aventis and Crucell Announce Strategic Agreement to Develop and Commercialize...
- Press release article from: PR Newswire January 7, 2004 700+ words
...For Japan, Aventis Pasteur will supply...products to Crucell, and Crucell will pay a royalty on sales to Aventis Pasteur. Aventis Pasteur...that combining Crucell's PER.C6...technology with Aventis Pasteur's market leadership...
- AERAS/CRUCELL TO DEVELOP TB VACCINE.
- Newspaper article from: Worldwide Biotech May 1, 2004 700+ words
...production technology of choice for Crucell's current and potential pharmaceutical...biotechnology partners. About Crucell Crucell N.V. is a biotechnology company...programs include collaborations with Aventis Pasteur for influenza vaccines, the...
- Crucell Signs Up Another PER.C6 Customer, Enters Deal With GSK.(GlaxoSmithKline...
- Magazine article from: BIOWORLD Today Pihl-Carey, Karen August 16, 2004 700+ words
...production of classical vaccines. Crucell started as a gene therapy...antibodies. Two years ago, Crucell launched it for fully human...changed the company's name to Crucell. U-Bisys brought its antibody...agreement worth $38 million with Aventis Pasteur, the vaccines business of...
- Crucell Signs Up Another PER.C6 Customer, Enters Deal With GSK.
- Magazine article from: BIOWORLD Today November 3, 2009 700+ words
...production of classical vaccines. Crucell started as a gene therapy...antibodies. Two years ago, Crucell launched it for fully human...changed the company's name to Crucell. U-Bisys brought its antibody...agreement worth $38 million with Aventis Pasteur, the vaccines business of...
- Crucell and Vaxin Announce PER.C6 Licensing Agreement; Vaxin Technology...
- Press release article from: PR Newswire September 13, 2004 700+ words
...tetanus/diphtheria. About Crucell Crucell N.V. is a biotechnology company...programs include collaborations with Aventis Pasteur for influenza vaccines, the...University for a malaria vaccine. Crucell's products are based on its...
- MorphoSys Obtains License on Crucell Human Cell Line.
- Press release article from: PR Newswire September 8, 2004 700+ words
...www.morphosys.com/. About Crucell: Crucell N.V. is a biotechnology company...programs include collaborations with Aventis Pasteur for influenza vaccines, the...University for a malaria vaccine. Crucell's products are based on its...
- Crucell's sales and net loss rise for the quarter.(Brief Article)
- Newspaper article from: Pharma Marketletter April 19, 2004 700+ words
Crucell reported revenues for the first quarter...revenues posted under its agreement with Aventis Pasteur for the co-development of a new generation...equating to a substantial increase of 94%. Crucell largely attributes the rise in net loss...
